Hhr Asset Management, LLC Allogene Therapeutics, Inc. Transaction History

Hhr Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $1.25 Million - $1.9 Million	-48,650 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$25.24 - $43.45 $425,546 - $732,567	-16,860 Reduced 25.74%	48,650 $1.23 Million
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $120,777 - $167,700	-3,730 Reduced 5.39%	65,510 $2.47 Million
Q2 2020 Aug 07, 2020	SELL	$18.39 - $54.04 $210,565 - $618,758	-11,450 Reduced 14.19%	69,240 $2.96 Million
Q4 2019 Feb 14, 2020	SELL	$24.82 - $31.4 $200,297 - $253,398	-8,070 Reduced 9.09%	80,690 $2.1 Million
Q2 2019 Aug 14, 2019	BUY	$25.56 - $31.09 $2.27 Million - $2.76 Million	88,760 New	88,760 $2.38 Million

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $328M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Hhr Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Hhr Asset Management, LLC with notifications on news.